NCT04845880

SARS Cov_2 Incidence of Healthy Health Workers

Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 Patients in Our Hospital

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 182 (actual)
• Sponsor: Baskent University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.

Conditions

• SARS COV-2 IgG Levels on Health Workers

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2	Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

Timeline

• Start date: 2020-10-01
• Primary completion: 2021-03-01
• Completion: 2021-04-01
• First posted: 2021-04-15
• Last updated: 2021-04-15

Locations

1 site across 1 country: Turkey (Türkiye)